(Q38124062)

29 August 2017

Influenza virosomes as vaccine adjuvant and carrier system (English)

1 reference

29 August 2017

1 reference

Christian Moser

1

1 reference

29 August 2017

Matthias Müller

2

1 reference

29 August 2017

Matthias D Kaeser

3

1 reference

29 August 2017

Ulrike Weydemann

4

1 reference

29 August 2017

Mario Amacker

5

1 reference

29 August 2017

1 July 2013

1 reference

Expert Review of Vaccines

29 August 2017

1 reference

29 August 2017

12

1 reference

29 August 2017

7

1 reference

29 August 2017

779-791

1 reference

Formation of virosomes from influenza subunits and liposomes

29 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Effective subunit vaccines against an enveloped animal virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Structures of virus and virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

The coming of age of virus-like particle vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Virus-like particles: passport to immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

The application of virus-like particles to human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Developments in virus-like particle-based vaccines for infectious diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Virosome: a novel vector to enable multi-modal strategies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Cellular delivery of siRNA mediated by fusion-active virosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Pseudovirions as vehicles for the delivery of siRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Epaxal: a virosomal vaccine to prevent hepatitis A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Intranasal immunization against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Immunostimulating reconstituted influenza virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

The virosome concept for influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Influenza virosomes as a vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Modified influenza virosomes: recent advances and potential in gene delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Virosomes for antigen and DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Nanoparticles target distinct dendritic cell populations according to their size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

Efficient delivery of DNA to dendritic cells mediated by influenza virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811195

10.1586/14760584.2013.811195

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference